HDAC1: A Potential Drug Target and Biomarker (G3065)

Target Name: HDAC1

NCBI ID: G3065

HDAC1

HDAC1: A Potential Drug Target and Biomarker

Hydroxydeacetylase 1 (HDAC1) is a gene that encodes a protein involved in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The HDAC1 gene has been identified as a potential drug target and biomarker for several reasons, including its involvement in the development and progression of various diseases, its expression in a variety of tissues and cells, and its potential clinical applications in treatingHDAC1-related disorders.

TheHDAC1 gene encodes a protein that is involved in the metabolism of histones, which are important molecules found in the nucleus of a cell. Histones play a critical role in the regulation of gene expression, and alterations in their levels or structure can lead to the development of various diseases. TheHDAC1 gene has been shown to be involved in the regulation of several key genes involved in the development and progression of cancer, including the genes that encode the tumor suppressor protein p53 and the oncogene telomerase.

In addition to its involvement in cancer, the HDAC1 gene has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms associated with these diseases. TheHDAC1 gene has been shown to be involved in the regulation of the neurotransmitter dopamine, which is involved in the development and progression of these conditions.

TheHDAC1 gene has also been shown to be involved in the regulation of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. TheHDAC1 gene has been shown to be involved in the regulation of the immune response, which is thought to contribute to the development and progression of these conditions.

In addition to its involvement in disease, the HDAC1 gene has also been shown to be a potential biomarker for several diseases. TheHDAC1 gene has been shown to be expressed in a variety of tissues and cells, including brain, heart, and muscle cells. This makes it a potential target for drugs that can be used to treat diseases associated with the HDAC1 gene, such as cancer, neurodegenerative diseases, and autoimmune disorders.

TheHDAC1 gene has also been shown to be involved in the regulation of several key signaling pathways that are involved in the development and progression of disease. For example, the HDAC1 gene has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the development and progression of cancer. In addition, the HDAC1 gene has been shown to be involved in the regulation of the TGF-β signaling pathway, which is involved in the development and progression of neurodegenerative diseases.

In conclusion, the HDAC1 gene has been identified as a potential drug target and biomarker for several reasons, including its involvement in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. TheHDAC1 gene has also been shown to be involved in the regulation of several key signaling pathways that are involved in the development and progression of disease, making it a promising target for drugs that can be used to treat these conditions. Further research is needed to fully understand the role of the HDAC1 gene in disease and to develop effective treatments for HDAC1-related disorders.

Protein Name: Histone Deacetylase 1

Functions: Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4) (PubMed:16762839, PubMed:17704056, PubMed:28497810). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events (PubMed:16762839, PubMed:17704056). Histone deacetylases act via the formation of large multiprotein complexes (PubMed:16762839, PubMed:17704056). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). Also functions as deacetylase for non-histone targets, such as NR1D2, RELA, SP1, SP3 and TSHZ3 (PubMed:12837748, PubMed:16478997, PubMed:17996965, PubMed:19343227). Deacetylates SP proteins, SP1 and SP3, and regulates their function (PubMed:12837748, PubMed:16478997). Component of the BRG1-RB1-HDAC1 complex, which negatively regulates the CREST-mediated transcription in resting neurons (PubMed:19081374). Upon calcium stimulation, HDAC1 is released from the complex and CREBBP is recruited, which facilitates transcriptional activation (PubMed:19081374). Deacetylates TSHZ3 and regulates its transcriptional repressor activity (PubMed:19343227). Deacetylates 'Lys-310' in RELA and thereby inhibits the transcriptional activity of NF-kappa-B (PubMed:17000776). Deacetylates NR1D2 and abrogates the effect of KAT5-mediated relieving of NR1D2 transcription repression activity (PubMed:17996965). Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development (By similarity). Involved in CIART-mediated transcriptional repression of the circadian transcriptional activator: CLOCK-BMAL1 heterodimer (By similarity). Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex or CRY1 through histone deacetylation (By similarity). In addition to protein deacetylase activity, also has protein-lysine deacylase activity: acts as a protein decrotonylase by mediating decrotonylation ((2E)-butenoyl) of histones (PubMed:28497810)

The "HDAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HDAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets